vs
Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Pediatrix Medical Group, Inc. (MD). Click either name above to swap in a different company.
Pediatrix Medical Group, Inc. is the larger business by last-quarter revenue ($493.8M vs $487.7M, roughly 1.0× CLOVER HEALTH INVESTMENTS, CORP.). Pediatrix Medical Group, Inc. runs the higher net margin — 6.8% vs -10.1%, a 16.9% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs -1.7%). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs -0.1%).
Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.
Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.
CLOV vs MD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $487.7M | $493.8M |
| Net Profit | $-49.3M | $33.7M |
| Gross Margin | — | — |
| Operating Margin | -10.1% | 9.9% |
| Net Margin | -10.1% | 6.8% |
| Revenue YoY | 44.7% | -1.7% |
| Net Profit YoY | -123.2% | 10.5% |
| EPS (diluted) | — | $0.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $487.7M | $493.8M | ||
| Q3 25 | $496.6M | $492.9M | ||
| Q2 25 | $477.6M | $468.8M | ||
| Q1 25 | $462.3M | $458.4M | ||
| Q4 24 | $337.0M | $502.4M | ||
| Q3 24 | $331.0M | $511.2M | ||
| Q2 24 | $356.3M | $504.3M | ||
| Q1 24 | $346.9M | $495.1M |
| Q4 25 | $-49.3M | $33.7M | ||
| Q3 25 | $-24.4M | $71.7M | ||
| Q2 25 | $-10.6M | $39.3M | ||
| Q1 25 | $-1.3M | $20.7M | ||
| Q4 24 | $-22.1M | $30.5M | ||
| Q3 24 | $-9.2M | $19.4M | ||
| Q2 24 | $7.4M | $-153.0M | ||
| Q1 24 | $-19.2M | $4.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 24.5% | — | ||
| Q2 24 | 30.3% | — | ||
| Q1 24 | 23.6% | — |
| Q4 25 | -10.1% | 9.9% | ||
| Q3 25 | -4.9% | 13.8% | ||
| Q2 25 | -2.2% | 12.8% | ||
| Q1 25 | -0.3% | 7.0% | ||
| Q4 24 | -6.4% | 7.8% | ||
| Q3 24 | -2.7% | 6.6% | ||
| Q2 24 | 2.0% | -31.3% | ||
| Q1 24 | -6.5% | 3.2% |
| Q4 25 | -10.1% | 6.8% | ||
| Q3 25 | -4.9% | 14.5% | ||
| Q2 25 | -2.2% | 8.4% | ||
| Q1 25 | -0.3% | 4.5% | ||
| Q4 24 | -6.6% | 6.1% | ||
| Q3 24 | -2.8% | 3.8% | ||
| Q2 24 | 2.1% | -30.3% | ||
| Q1 24 | -5.5% | 0.8% |
| Q4 25 | — | $0.40 | ||
| Q3 25 | — | $0.84 | ||
| Q2 25 | — | $0.46 | ||
| Q1 25 | — | $0.24 | ||
| Q4 24 | — | $0.37 | ||
| Q3 24 | — | $0.23 | ||
| Q2 24 | — | $-1.84 | ||
| Q1 24 | — | $0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $78.3M | $375.2M |
| Total DebtLower is stronger | — | $570.5M |
| Stockholders' EquityBook value | $308.7M | $865.9M |
| Total Assets | $541.0M | $2.2B |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $78.3M | $375.2M | ||
| Q3 25 | — | $340.1M | ||
| Q2 25 | — | $224.7M | ||
| Q1 25 | — | $99.0M | ||
| Q4 24 | $194.5M | $229.9M | ||
| Q3 24 | $288.0M | $103.8M | ||
| Q2 24 | $254.8M | $19.4M | ||
| Q1 24 | $208.3M | $8.0M |
| Q4 25 | — | $570.5M | ||
| Q3 25 | — | $577.2M | ||
| Q2 25 | — | $583.9M | ||
| Q1 25 | — | $590.5M | ||
| Q4 24 | — | $597.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $308.7M | $865.9M | ||
| Q3 25 | $340.9M | $890.7M | ||
| Q2 25 | $344.2M | $833.8M | ||
| Q1 25 | $336.1M | $789.2M | ||
| Q4 24 | $341.1M | $764.9M | ||
| Q3 24 | $342.2M | $732.5M | ||
| Q2 24 | $324.9M | $706.5M | ||
| Q1 24 | $292.5M | $856.2M |
| Q4 25 | $541.0M | $2.2B | ||
| Q3 25 | $559.7M | $2.2B | ||
| Q2 25 | $575.0M | $2.1B | ||
| Q1 25 | $583.7M | $2.0B | ||
| Q4 24 | $580.7M | $2.2B | ||
| Q3 24 | $653.0M | $2.1B | ||
| Q2 24 | $674.2M | $2.0B | ||
| Q1 24 | $671.8M | $2.2B |
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | 0.70× | ||
| Q1 25 | — | 0.75× | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-66.9M | $114.1M |
| Free Cash FlowOCF − Capex | $-69.0M | — |
| FCF MarginFCF / Revenue | -14.1% | — |
| Capex IntensityCapex / Revenue | 0.4% | — |
| Cash ConversionOCF / Net Profit | — | 3.39× |
| TTM Free Cash FlowTrailing 4 quarters | $-69.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-66.9M | $114.1M | ||
| Q3 25 | $12.1M | $137.3M | ||
| Q2 25 | $5.4M | $137.2M | ||
| Q1 25 | $-16.3M | $-117.5M | ||
| Q4 24 | $34.8M | $133.0M | ||
| Q3 24 | $50.0M | $91.8M | ||
| Q2 24 | $44.8M | $107.0M | ||
| Q1 24 | $25.9M | $-125.2M |
| Q4 25 | $-69.0M | — | ||
| Q3 25 | $11.4M | — | ||
| Q2 25 | $4.8M | — | ||
| Q1 25 | $-16.5M | — | ||
| Q4 24 | $33.3M | — | ||
| Q3 24 | $49.6M | — | ||
| Q2 24 | $44.4M | — | ||
| Q1 24 | $25.5M | — |
| Q4 25 | -14.1% | — | ||
| Q3 25 | 2.3% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | -3.6% | — | ||
| Q4 24 | 9.9% | — | ||
| Q3 24 | 15.0% | — | ||
| Q2 24 | 12.5% | — | ||
| Q1 24 | 7.3% | — |
| Q4 25 | 0.4% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | 3.39× | ||
| Q3 25 | — | 1.91× | ||
| Q2 25 | — | 3.49× | ||
| Q1 25 | — | -5.66× | ||
| Q4 24 | — | 4.36× | ||
| Q3 24 | — | 4.72× | ||
| Q2 24 | 6.04× | — | ||
| Q1 24 | — | -31.03× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLOV
Segment breakdown not available.
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
